U.S. Judge clears way for Maryland Drug Price-Gouging law


U.S. judge clears way for Maryland Medication price-gouging law

Pharmaceutical companies have so far dodged stricter national oversight of medication costs despite growing outrage over hikes by companies like Mylan NV and Valeant Pharmaceuticals International Inc. However, states, struggling to pay rising healthcare costs, are currently taking the fight up.

Maryland’s law was passed by the state legislature in April, and a Republican, Governor Larry Hogan, said that he would let it take effect without his signature.

The attorney general can also require a manufacturer or distributor to show its records and justify a price increase.

Released at Fri, 29 Sep 2017 18:10:58 +0000
The state law will go into effect as planned on Sunday, according to Maryland Attorney General Brian Frosh’s office.
Off-patent or medications. The law does not apply to drugs that are still under patent protection.

Under the statute, Maryland will field complaints and explore “unconscionable increases” in costs for essential
U.S. District Judge Marvin Garbis wrote that lawsuit can continue under the trade group’s argument that the law is too vague, but he dismissed other arguments.

(Reuters) – A U.S. District Court judge on Friday cleared the way for Maryland to implement the country’s first law designed to punish drugmakers for price gouging by denying the generic drug industry trade group’s request for an injunction.
At least 176 statements on pricing and payment have been introduced this year according to the National Conference of State Legislatures.

The trade group said it will appeal the decision of the court.

“This legislation will hurt patient access to secure, affordable generic medicines in Maryland and the rest of the U.S., and will create untenable doubt for generic drug makers who might be left with no alternative but to abandon markets entirely,” Jeff Francer, AAM general counsel, said in a statement.